Technetium-99m Sulfur Colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of PEGylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (EOC)
Hugh Giovinazzo, BSc, PharmD, Candidate1, Parag Kumar, PharmD1, Arif Sheikh, MD2, Marija Ivanovic, PhD2, Mark D. Walsh, PharmD3, Whitney P. Caron, PharmD1, Gina Song, PharmD1, Ann B. Whitlow, RT, CNMT4, Suzanne E. Newman, BSc4, Nihn La-Beck, PharmD5, Richard J. Kowalsky, PharmD4, Beth A. Zamboni, MS6, Daniel L. Clarke-Pearson, MD7, Wendy R. Brewster, MD7, Linda Van Le, MD7, Victoria Lin Bae-Jump, MD, PhD4, Paola A. Gehrig, MD7 and William C. Zamboni, PharmD, PhD1
1University of North Carolina at Chapel Hill School of Pharmacy Division of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC
2University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
3Mount Auburn Hospital, Cambridge, MA
4University of North Carolina at Chapel Hill, Chapel Hill, NC
5Texas Tech University, Abilene, TX
6Carlow University, Pittsburgh, PA
7University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC